| 1. |
Roesel C, Welter S, Kambartel KO, et al. Prognostic markers in resected large cell neuroendocrine carcinoma: a multicentre retrospective analysis. J Thorac Dis, 2020, 12(3): 466-476.
|
| 2. |
Huang L, Feng Y, Xie T, et al. Incidence, survival comparison, and novel prognostic evaluation approaches for stage III-IV pulmonary large cell neuroendocrine carcinoma and small cell lung cancer. BMC Cancer, 2023, 23(1): 312.
|
| 3. |
Velcheti V, Schalper K. Basic overview of current immunotherapy approaches in cancer. Am Soc Clin Oncol Educ Book, 2016, 35: 298-308.
|
| 4. |
Sherman S, Rotem O, Shochat T, et al. Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer, 2020, 143: 40-46.
|
| 5. |
Dudnik E, Kareff S, Moskovitz M, et al. Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. J Immunother Cancer, 2021, 9(2): e001999.
|
| 6. |
Watanabe M, Matsumura Y, Yamaguchi H, et al. Large cell neuroendocrine carcinoma of the lung controlled for 4 years by a single administration of pembrolizumab: a case report. Thorac Cancer, 2022, 13(19): 2817-2822.
|
| 7. |
Patel SP, Othus M, Chae YK, et al. A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors. Clin Cancer Res, 2020, 26(10): 2290-2296.
|
| 8. |
Gelsomino F, Lamberti G, Tiseo M, et al. Atezolizumab in a CoHort of pretreated, advanced, non-small cell lung cancer patients with rare HistologiCal SubtypEs (CHANCE trial). Ther Adv Med Oncol, 2020, 12: 1758835920915983.
|
| 9. |
Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med, 2012, 366(26): 2443-2454.
|
| 10. |
Kim HS, Lee JH, Nam SJ, et al. Association of PD-L1 expression with tumor-infiltrating immune cells and mutation burden in high-grade neuroendocrine carcinoma of the lung. J Thorac Oncol, 2018, 13(5): 636-648.
|
| 11. |
Eichhorn F, Harms A, Warth A, et al. PD-L1 expression in large cell neuroendocrine carcinoma of the lung. Lung Cancer, 2018, 118: 76-82.
|
| 12. |
Tsuruoka K, Horinouchi H, Goto Y, et al. PD-L1 expression in neuroendocrine tumors of the lung. Lung Cancer, 2017, 108: 115-120.
|
| 13. |
Inamura K, Yokouchi Y, Kobayashi M, et al. Relationship of tumor PD-L1 (CD274) expression with lower mortality in lung high-grade neuroendocrine tumor. Cancer Med, 2017, 6(10): 2347-2356.
|
| 14. |
Wang VE, Urisman A, Albacker L, et al. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother Cancer, 2017, 5(1): 75.
|
| 15. |
Zhang X, Sun Y, Miao Y, et al. Immune checkpoint inhibitor therapy achieved complete response for drug-sensitive EGFR/ALK mutation-negative metastatic pulmonary large-cell neuroendocrine carcinoma with high tumor mutation burden: a case report. Onco Targets Ther, 2020, 13: 8245-8250.
|
| 16. |
Hermans BCM, Derks JL, Thunnissen E, et al. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC). Lung Cancer, 2019, 130: 179-186.
|
| 17. |
Yin L, Xue J, Li R, et al. Effect of low-dose radiation therapy on abscopal responses to hypofractionated radiation therapy and anti-PD1 in mice and patients with non-small cell lung cancer. Int J Radiat Oncol Biol Phys, 2020, 108(1): 212-224.
|
| 18. |
Zhou X, Zhou L, Yao Z, et al. Safety and tolerability of low-dose radiation and stereotactic body radiotherapy + sintilimab for treatment-na?ve stage IV PD-L1+ non-small cell lung cancer patients. Clin Cancer Res, 2023, 29(20): 4098-4108.
|
| 19. |
Vaios EJ, Winter SF, Shih HA, et al. Novel mechanisms and future opportunities for the management of radiation necrosis in patients treated for brain metastases in the era of immunotherapy. Cancers (Basel), 2023, 15(9): 2432.
|
| 20. |
Miller JA, Bennett EE, Xiao R, et al. Association between radiation necrosis and tumor biology after stereotactic radiosurgery for brain metastasis. Int J Radiat Oncol Biol Phys, 2016, 96(5): 1060-1069.
|
| 21. |
Tye K, Engelhard HH, Slavin KV, et al. An analysis of radiation necrosis of the central nervous system treated with bevacizumab. J Neurooncol, 2014, 117(2): 321-327.
|
